Search Results | Blood | American Society of Hematology

1-20 of 87

2 3 4 5

Sort by

Sort Order Select

Journal Articles

By any other name …

Mark Levis

Blood (2022) 140 (15): 1657–1658.

DOI: https://doi.org/10.1182/blood.2022018005

Published: 2022

Journal Articles

Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease

Sabine Kayser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, Nydia Panitz, Andrew M. Brunner, Matthias Fante, Christoph Lutz, Daniel Wolff, Anthony D. Ho, Mark Levis, Richard F. Schlenk, Cristina Papayannidis

Blood (2021) 138 (Supplement 1): 3404.

DOI: https://doi.org/10.1182/blood-2021-147446

Published: 2021

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

DOI: https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Theodoros Karantanos, Hua-Ling Tsai, Mark Levis, Ravi Varadhan, Richard J. Jones, Tania Jain

Blood (2021) 138 (Supplement 1): 1520.

DOI: https://doi.org/10.1182/blood-2021-151624

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

DOI: https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Vinod A. Pullarkat, Mark Levis, Gabriel N. Mannis, Stephen A Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Harry P. Erba

Blood (2021) 138 (Supplement 1): 1268.

DOI: https://doi.org/10.1182/blood-2021-148054

Published: 2021

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

DOI: https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

DOI: https://doi.org/10.1182/blood-2021-150281

Published: 2021

Journal Articles

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Theodoros Karantanos, MDPhD, Hua-Ling Tsai, ScM, Lukasz P. Gondek, MDPhD, Mark Levis, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Ivana Gojo, MD, Ravi Varadhan, PhD, Richard J. Jones, MD, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 40.

DOI: https://doi.org/10.1182/blood-2020-138671

Published: 2020

Journal Articles

Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

John-William Sidhom, MSc, Ingharan J Siddarthan, Bo-Shiun Lai, PhD, Adam Luo, Bryan Hambley, MD, Jennifer Bynum, MD, Amy S. Duffield, MD PhD, Michael B. Streiff, MD, Alison R. Moliterno, MD, Philip H. Imus, MD, Christian B. Gocke, MD PhD, Lukasz P. Gondek, MDPhD, Amy E. DeZern, MD, Alexander S Baras, MDPhD, Thomas S. Kickler, MD, Mark Levis, MD PhD, Eugene Shenderov, MDDPhil

Blood (2020) 136 (Supplement 1): 10–12.

DOI: https://doi.org/10.1182/blood-2020-135836

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

DOI: https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

DOI: https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD

Blood (2020) 136 (Supplement 1): 20–22.

DOI: https://doi.org/10.1182/blood-2020-139705

Published: 2020

Journal Articles

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Alexander E. Perl, MD, Jessica K. Altman, MD, Naoko Hosono, MD PhD, Pau Montesinos, MD PhD, Nikolai A. Podoltsev, MD PhD, Giovanni Martinelli, MD, Catherine C. Smith, MD, Mark Levis, MD PhD, Christoph Röllig, Prof., MD, Marco Groß-Langenhoff, PhD, Nahla Hasabou, MD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 22–23.

DOI: https://doi.org/10.1182/blood-2020-136395

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

DOI: https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

DOI: https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

DOI: https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-140176

Published: 2020

Journal Articles

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung, Vinod A. Pullarkat, MD

Blood (2020) 136 (Supplement 1): 26–28.

DOI: https://doi.org/10.1182/blood-2020-136868

Published: 2020

Journal Articles

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, Alexander E. Perl, MD, Mark Levis, MD PhD, Catherine C. Smith, MD, Andrew M. Brunner, Koichi Takahashi, MD PhD, Philip C. Amrein, MD, Hanno R. Hock, MD PhD, Gabriela S. Hobbs, MD, Rupa Narayan, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Naval Daver, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-140118

Published: 2020

2 3 4 5

NARROW

By any other name …

Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only